Exposure by Assessment: Effects of Daily AMQ-Based EMA of an Intrusive Trauma Memory in PTSD (NCT07658157) | Clinical Trial Compass
RecruitingNot Applicable
Exposure by Assessment: Effects of Daily AMQ-Based EMA of an Intrusive Trauma Memory in PTSD
Israel50 participantsStarted 2026-06-14
Plain-language summary
Intrusive re-experiencing is a hallmark of PTSD. The study applies ecological momentary assessment (EMA) of participants' trauma memories (active group) vs. EMA of a neutral memory (control group) to test whether the active intervention can reduce intrusive symptoms severity and overal PTSD symptom severity in general.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18-70
* Posttraumatic stress disorder
* intrusive symptoms.
Exclusion Criteria:
* Psychotic or bipolar disorder
* Heavy use of drugs or alcohol
* Prominent personality disorder
* Significant risk of harm to self or others
* Current trauma-focused treatment
* Reporting intrusions as thoughts only rather than as memories
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial uses something called AMQ-based EMA — which seems to involve repeatedly assessing a traumatic memory daily — can you explain what that process would actually feel like for me, and whether repeatedly engaging with a trauma memory in this way could make my PTSD symptoms worse before they get better?
2Since this study is listed as Phase NA, it sounds like it may be more of a research or feasibility study than a standard treatment trial — does that mean there's less safety and effectiveness data than there would be for a drug or therapy that's already gone through clinical phases, and what does that mean for me personally?
3The trial is measuring changes using something called the CAPS-5, which I understand is a clinician-rated scale for PTSD severity — how often would I be assessed, and what happens if my scores get significantly worse during the study?
4Before considering a study like this, is there a standard evidence-based PTSD treatment — like Prolonged Exposure or Cognitive Processing Therapy — that might be worth trying first, and how would you compare the potential benefits and risks of those options against participating in this trial?
5How much time and commitment would this trial realistically require from me on a daily basis, and given that it involves daily monitoring of an intrusive trauma memory, is there any support or clinical oversight built in if I'm struggling between check-ins?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change from Baseline in Clinician-Rated PTSD Symptom Severity as Assessed by the CAPS-5 Total Severity Score at Post-Intervention and Follow-Up
Timeframe: From baseline to post-intervention - 10 days; Follow-up data will be collected 15-30 days following the post-intervention assessment.
2
Change from Baseline in Clinician-Rated PTSD Intrusion Symptom Severity as Assessed by the CAPS-5 Cluster B Severity Score at Post-Intervention and Follow-Up
Timeframe: From baseline to post-intervention - 10 days; Follow-up data will be collected 15-30 days following the post-intervention assessment.